6533b861fe1ef96bd12c57b9
RESEARCH PRODUCT
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
C. OlivierRocío BenitoEva LumbrerasJuan Luis GarcíaJosep-maria RiberaCarlos GrandeLuis A. Corchete-sánchezAlfonso García De CocaJesus M Hernández-sánchezMaribel Forero-castroMaribel Forero-castroJordi RiberaPere BarbaEstrella CarrilloMaría Hernández-sánchezLourdes EscodaCristina RobledoJavier MenárguezJesús M. Hernández-rivasMar Tormosubject
OncologyMalemedicine.medical_treatmentarray-based comparative genomic hybridization (aCGH)Intensive chemotherapyKaplan-Meier EstimateBioinformatics0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy ProtocolsYoung adultComparative Genomic HybridizationGenomeArray-based comparative genomic hybridizationBurkitt lymphomaHigh-Throughput Nucleotide SequencingHematologyMiddle AgedPrognosisBurkitt Lymphomahumanities3. Good healthTreatment Outcome030220 oncology & carcinogenesisoutcomeRituximabFemaleRituximabmedicine.drugAdultmedicine.medical_specialtyAdolescenteducationBiologyNext-generation sequencing outcome03 medical and health sciencesYoung AdultInternal medicinemedicineHumansIn patientAgedChromosome AberrationsChemotherapymedicine.diseaseGNA13Lymphomastomatognathic diseasesnext-generation sequencing030215 immunologyComparative genomic hybridizationdescription
Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015.
year | journal | country | edition | language |
---|---|---|---|---|
2015-11-16 |